---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-030746"
form_type: "8-K"
ticker: "CODX"
cik: "0001692415"
company_name: "Co-Diagnostics, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:03:00.296744+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Co-Diagnostics Q2 revenue jumps to $2.7M, net loss narrows to $7.6M, submits 510(k) for PCR platform

## Summary
- Revenue of $2.7M vs $0.2M in prior year, driven by milestone achievements on grants.
- Net loss of $7.6M ($0.25/share) improved from $8.9M ($0.31/share) YoY; adjusted EBITDA loss of $5.9M.
- Operating loss of $7.7M compared to $12.0M in 2023; cash and securities of $44.9M as of June 30.
- Submitted first 510(k) for Co-Dx PCR Pro platform with OTC COVID-19 test to FDA.
- Opened new manufacturing facility in South Salt Lake for Co-Primers and PCR platform components.

## SEC filing metadata
- accession: 0001493152-24-030746
- form_type: 8-K
- ticker: CODX
- cik: 0001692415
- company_name: Co-Diagnostics, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1692415/000149315224030746/0001493152-24-030746-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1692415/000149315224030746/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-030746
- JSON: https://secwatch.observer/filing/0001493152-24-030746.json
- Plain text: https://secwatch.observer/filing/0001493152-24-030746.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.